Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation

Background Little direct information is available on the effect of C-Reactive Protein (CRP) lowering on the reduction of recurrent atrial. fibrillation (AF). Methods and Results We compared tow-dose glucocorticoid therapy (16 mg methylprednisolone for 4 weeks tapered to 4 mg for 4 months) and placebo in 104 patients who had experienced persistent AF with a median concentration of CRP 1.14 mg/dL (min = 0.01, max = 2.58). Methy[prednisolone reduced recurrent AF (primary end-point) from 50% in the placebo group to 9.6% in the glucocorticoid group and permanent AF (expanded end-point) from 29% in the placebo group to 2% in the glucocorticoid group. Survival distributions for methylprednisolone were significantly different (for both primary and expanded end-point, P < 0.001). In multivariate Cox analysis, average CRP concentrations during follow-up were significant predictors of the primary end-point, with a relative risk 6.72 (P = 0.006) and the expanded end-point, with a relative risk of 11.67 (P = 0.0006). Conclusions CRP concentration is a risk factor for recurrent and permanent AF. Methylprednisolone successfully prevents recurrent and permanent AF. (C) 2004 Published by Elsevier Ltd on behalf of The European Society of Cardiology.